摘要
目的:观察糖胃安对四氧嘧啶糖尿病胃轻瘫模型大鼠5-羟色胺2A(5-HT2A)受体的影响并探讨其作用机制。方法:以四氧嘧啶加200%熟地黄浓煎液造成四氧嘧啶糖尿病胃轻瘫模型大鼠,将40只该模型大鼠随机分为4组:糖胃安高剂量组在用格列齐特片20mg·kg-1的基础上,给予糖胃安31.75g·kg-1灌胃;糖胃安低剂量组在用格列齐特片20mg·kg-1的基础上,给予糖胃安15.88g·kg-1灌胃;阳性对照药吗叮啉组在用格列齐特20mg·kg-1的基础上,联合吗丁啉3.75mg·kg-1配合灌胃;模型对照组给予等量蒸馏水。另取10只正常大鼠作为正常对照组。本实验采用免疫组化方法观察中药糖胃安对该模型大鼠受体的影响。结果:糖胃安不仅能降低糖尿病胃轻瘫模型大鼠血糖,还可以明显改善大鼠胃肠5-羟色胺2A受体水平。与用药前相比,有显著性差异(P<0.01),与对照组相比,也有显著性差异(P<0.05)。结论:5-HT2A受体含量的增高是糖尿病胃轻瘫的重要原因之一,糖胃安能够明显改善5-HT2A受体水平,有显著的降低血糖、改善患者症状的作用。
Objective: To observe the effects of Tangweian granule on 5-HT2A R in rat model with diabetic gastroparesis (DGP). Method: The rats with diabetic gastroparesis induced by injecting alloxan and giving 200% Radix Rehmanniae preparata were divided into four groups randomly: Tangweian high dosage group, Tangweian low dosage group, motilium control group and the model control group, 10 rats each group. Each group was irrigated with drugs during establishing the model. Additionally, we chose 10 rats by way of normal control group. Further more, Tangweian high dosage group were irrigated stomach with gliclazide 20 mg· kg^-1 and Tangweian granule 31.75 mg· kg^-1 ; Tangweian low dosage group were irrigated stomach with gliclazide 20 mg· kg^-1 and Tangweian granule 15.88 mg· kg^-1; motilium control group were irrigated stomach with gliclazide 20 mg· kg^-1 and motilium 3.75mg· kg^-1and the model control group were irrigated stomach with distilled water. Then the effects of Tangweian granule on 5-HT2A R were observed. Result: The curative group had better effects than the control group in lowering the blood sugar and the level of 5-HT2AR content (P 〈 0. 01 ). And there was significant difference between the curative group and control group (P 〈 0. 05 ). Conclusion: It is verified that Tangweian granule has obvious effects on lowering the blood sugar and improving the level of 5-HT2AR.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2008年第5期541-544,共4页
China Journal of Chinese Materia Medica
基金
山东省中医药卫生科研计划(2005-181)
关键词
糖胃安
糖尿病胃轻瘫
5-羟色胺2A
受体
Tangweian granule
diabetic gastroparesis
serotonin type2A receptor